Who Paid My Doc
Herman Feringa
Cardiovascular Disease Palmer, AK Medical Doctor
NPI 1356597827 CMS profile 772105
2490 S Woodworth Loop Ste 250, Palmer, AK 99645
General payments
$1,119
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Herman Feringa of Palmer, AK is reported in the CMS Open Payments database as having received $1,119 across 49 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 40th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $19 | 1 | |
| 2023 | General | $40 | 2 | |
| 2022 | General | $227 | 8 | |
| 2021 | General | $319 | 12 | |
| 2020 | General | $163 | 9 | |
| 2019 | General | $350 | 17 |
Beside peers
- Herman Feringa
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Herman Feringa were reported at $19. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Herman Feringa | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $350 | $450 | $127–$1,392 | $163 |
| 2020 | $163 | $242 | $77–$751 | $114 |
| 2021 | $319 | $335 | $101–$1,037 | $132 |
| 2022 | $227 | $395 | $121–$1,211 | $149 |
| 2023 | $40 | $443 | $136–$1,283 | $160 |
| 2024 | $0 | $450 | $136–$1,323 | $164 |
| 2025 | $19 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 39 drugsPart D claims
3,503
Drug cost
$676,261
Branded share of claims
23.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 279 | $385,968 | |
| Entresto Sacubitril/Valsartan | Brand | 107 | $131,153 | |
| Xarelto Rivaroxaban | Brand | 34 | $45,238 | |
| Repatha Sureclick Evolocumab | Brand | 30 | $33,560 | |
| Jardiance Empagliflozin | Brand | 27 | $28,909 | |
| Metoprolol Succinate | Generic | 469 | $8,038 | |
| Rosuvastatin Calcium | Generic | 356 | $7,080 | |
| Atorvastatin Calcium | Generic | 331 | $4,411 | |
| Ezetimibe | Generic | 103 | $3,238 | |
| Losartan Potassium | Generic | 272 | $2,976 |
The 10 drugs with the highest cost, of 39 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 67 billing codesPaid by Medicare
$349,713
Medicare patients
1,214
Services billed
16,361
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 54% | |
| Arthritis | 46% | |
| Atrial fibrillation | 32% | |
| Diabetes | 31% | |
| Heart failure | 25% | |
| COPD | 22% | |
| Chronic kidney disease | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, regadenoson, 0.1 mg J2785 | Office | 97 | 388 | $2,104 |
| Injection, perflutren lipid microspheres, per ml Q9957 | Office | 25 | 50 | $1,654 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 | Office | 139 | 11,837 | $1,224 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
49 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Alaska
Suneet Purohit
Cardiovascular Disease · Anchorage, AK
Ahmed Abuzaid
Cardiovascular Disease · Anchorage, AK
Danielle Veronneau
Cardiovascular Disease · Jber, AK
Hanna Konarzewska
Cardiovascular Disease · Fairbanks, AK
Jeffrey Dixson
Cardiovascular Disease · Anchorage, AK
Brian Scully
Cardiovascular Disease · Anchorage, AK
Related records
Cardiovascular Disease in Alaska
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Alaska
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.